JEWJITSU PEPTIDES: Research roundup: PCOS cardiovascular links, peptide‑coupled RBCs in MS, and β‑strand licensing of type IV pili

This focused narrative review synthesizes evidence linking polycystic ovary syndrome (PCOS) to cardiometabolic abnormalities beyond reproductive features. The review reports an estimated prevalence of PCOS in reproductive‑age women, discusses mechanistic connections such as hyperandrogenism contributing to insulin resistance and downstream dyslipidemia, hypertension, fatty liver, and endothelial dysfunction, and highlights chronic low‑grade inflammation and sympathetic overactivation as BMI‑independent amplifiers. The authors summarize subclinical vascular markers (increased carotid intima‑media thickness, elevated coronary artery calcium, and biomarkers including asymmetric dimethylarginine and plasminogen activator inhibitor‑1) and note a meta‑analysis reported pooled odds ratios for myocardial infarction and stroke. They emphasize that cardiometabolic risk can affect lean as well as overweight women with PCOS and that current risk stratification tools and cardiology guidelines inadequately account for PCOS.

An open‑label, dose‑escalation phase Ib trial examined autologous red blood cells chemically coupled with seven immunodominant myelin peptides (pcRBCs) as a tolerizing therapy in multiple sclerosis. The report states pcRBCs were safe and well tolerated in the studied cohort and that several clinical and imaging readouts remained stable after administration. Mechanistic findings included a reported reduction in neurofilament light chain consistent with lower tissue inflammation, single‑cell RNA sequencing evidence of expansion of antigen‑specific CD4+ memory T cells with regulatory phenotypes and loss of proinflammatory cells three months after one dose, and corroborating signals such as reduced autoreactive CD4+ responses and early increases in IL‑10, Tr1 cells, tolerogenic monocytes and plasmacytoid dendritic cells. Biodistribution data in mice and humans indicated rapid processing of pcRBCs by liver Kupffer cells and splenic marginal‑zone macrophages. The authors describe pcRBCs as a candidate autologous cell therapy for antigen‑specific tolerance, while the report remains an early phase, mechanistic clinical study rather than proof of clinical efficacy.

A structural, genetic, and biochemical study dissects how PilC/PilY1 adhesins promote assembly of type IV pili (T4P). Using Neisseria gonorrhoeae and Acinetobacter baylyi, the authors identify a short C‑terminal peptide in PilC/PilY1 that initiates pilus polymerization via β‑strand addition with PilK‑family minor pilins; this terminal β‑strand is described as necessary and partially sufficient to trigger fiber assembly. The proposed working model has a PilK–PilC/PilY1 complex recognized by a PilI–PilJ heterodimer to form a quaternary “licensing complex” that templates initiation. The paper further compares related systems: in type II secretion systems PilK homologs supply the β‑strand directly, and in Tad T4P a PilK‑like protein (CpaL/TadG) fulfills a similar role, exemplified by Caulobacter crescentus CpaL. These results are presented as a unifying structural mechanism (β‑strand addition) that helps explain tip retention under mechanical load and the diversity of filament assembly strategies across systems.